Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2026 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,...
May 05, 2026 16:01 ET | Source: Avalyn Pharma Inc.

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious,...
May 01, 2026 16:01 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Avalyn Pharma (Nasdaq: AVLN), a clinical-stage inhaled respiratory therapeutics company, closed its IPO at $345M with full overallotment exercised.
April 29, 2026 21:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Pricing of Upsized Initial Public Offering

BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm...
April 27, 2026 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

Avalyn Pharma strengthens leadership team with appointments of Adam Golden as General Counsel & Head of BD and Frank Salisbury as SVP, Commercial.
April 08, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

New York, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of...
April 06, 2026 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors

BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment...
March 25, 2026 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis

BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment...
March 23, 2026 16:01 ET | Source: Avalyn Pharma Inc.

Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Avalyn, a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases,...
March 05, 2026 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors

BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...